Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients
The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission/assent will receive the commercial MMR vaccine according to product indication and labeling.
• Received a heart transplant
• At least 1 year after transplant
• At least 1 year after antibody-mediated rejection treatment (intravenous immune globulin, rituximab, bortezomib, plasmapheresis, carfilzomib, eculizumab, daratumumab)
• At least 1 year from anti-thymocyte globulin
• At least 6 months after pulse dose steroid treatment or basiliximab treatment
• No history of MMR vaccination OR History of MMR vaccination but seronegativity for measles at time of inclusion
• Clinically well